Cure8 research brief
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and differences by residence and treatment patterns that could affect care access and outcomes.
Adult patients with Crohn’s disease or ulcerative colitis, clinicians and health services researchers interested in IBD epidemiology, and policymakers focused on IBD care delivery and access in Central Asia.
This paper reports a cross-sectional analysis of Kazakhstan’s national multicenter IBD registry (2021–2024) describing demographics, disease activity (Mayo score for UC; Harvey–Bradshaw for CD), treatment patterns, and factors associated with clinically active disease at enrollment.
The study found that 77.5% of registered patients had active disease at enrollment and identified different factors associated with activity in UC versus CD (for example, corticosteroid use and frequent exacerbations were linked to higher odds of activity). Biologic therapy was not independently associated with activity in adjusted models.
The findings are associations from registry enrollment visits and do not establish causation. The report is useful for understanding IBD care patterns and disease burden in a Central Asian national registry and highlights gaps in disease control at secondary/tertiary centers.
Because the analysis is cross-sectional, treatment-related associations may reflect confounding by indication (sicker patients more likely to be on certain therapies). The registry methods use standard clinical indices (Mayo, HBI), which supports comparability with other cohorts.
For patients and clinicians, the paper underscores a high prevalence of active disease among people captured by this registry and the need to examine access to maintenance therapies, treat-to-target approaches, and rural versus urban disparities in care. It does not provide evidence about effectiveness of specific drugs or long-term outcomes.
Results come from a cross-sectional registry enrollment visit (2021–2024) and report associations, not causal effects. Treatment-related associations may reflect confounding by indication. The article provides an abstract-level structured report from a peer-reviewed journal.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This large, population-level analysis summarizes long-term global trends in IBD burden and shows rising incidence and persistent geographic and socio-demographic inequalities. Patients and clinicians may see why...
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...
Rising IBD prevalence across Asia means more people will need diagnosis, long-term care, and health-system resources; patterns differ by country and by Crohn's disease versus ulcerative colitis, which affects planning...
